JPMorgan Chase & Co. Reiterates Overweight Rating for AstraZeneca (LON:AZN)

AstraZeneca (LON:AZN)‘s stock had its “overweight” rating reaffirmed by investment analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Tuesday,Digital Look reports.

Several other research analysts also recently commented on the stock. Shore Capital reissued a “buy” rating and set a £145 price objective on shares of AstraZeneca in a report on Thursday, November 6th. Jefferies Financial Group reiterated a “buy” rating and issued a £150 target price on shares of AstraZeneca in a research report on Monday, November 10th. Finally, Berenberg Bank raised their price target on AstraZeneca from £142 to £145 and gave the company a “buy” rating in a report on Tuesday, October 21st. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, AstraZeneca presently has a consensus rating of “Moderate Buy” and a consensus target price of £138.

AstraZeneca Price Performance

Shares of LON:AZN traded down GBX 20.31 during midday trading on Tuesday, reaching £142.04. 2,722,445 shares of the company were exchanged, compared to its average volume of 59,721,828. The stock has a market cap of £220.20 billion, a PE ratio of 23.59, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. The business’s fifty day moving average is £135.29 and its two-hundred day moving average is £121.88. AstraZeneca has a one year low of GBX 9,573.51 and a one year high of £143.12. The company has a current ratio of 0.93, a quick ratio of 0.59 and a debt-to-equity ratio of 73.83.

Insider Transactions at AstraZeneca

In related news, insider Nazneen Rahman sold 297 shares of the firm’s stock in a transaction on Thursday, December 18th. The stock was sold at an average price of £134.96, for a total value of £40,083.12. 0.14% of the stock is currently owned by corporate insiders.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.